Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 2/19/2019

|Includes: Akebia Therapeutics, Inc. (AKBA), ARGX, CPRX, FGEN, GRTS, RARX

This week we have Expert Calls on:FGEN, AKBA, GRTS, RARX, ARGX, CPRX.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Preparing for MACE Safety data read out for FibroGen's Roxadustat by discussing the data released to date

Ticker: FGEN, AKBA

Who's the Expert?

  • Emeritus Associate Professor of Clinical Medicine, Division of Nephrology at Indiana University.
  • Attends on Renal Services 12-18 weeks per year.
  • Investigator in multiple CKD clinical trials including epoetin alfa and darbepoetin alfa.

Interview Goal: With a major readout for Roxadustat safety coming up, we will dig into the elements of the MACE endpoint and possible outcomes.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: Looking at the newly IPO’d Gritstone Oncology’s lead pipeline candidate, GRANITE-001, personalized neoantigen immunotherapy in treating solid tumors

Ticker: GRTS

Who's the Expert?

  • Associate Professor of Medicine at Cleveland Clinic Lerner College of Medicine of Case Western and oncologist and the quality improvement officer at the Cleveland Clinic Taussig Cancer Institute.
  • Currently manages 400 active patients with solid tumors.
  • Research focuses on immune based therapies in breast cancer and other solid malignancies, and better understanding the various mechanisms by which tumors evade the immune system; Principal Investigator in over 30 clinical trials.

Interview Goal: To understand the market potential of Gritstone’s GRANITE-001 in the treatment of solid tumors.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: Looking at The Top 3 Upcoming Therapies in Myasthenia Gravis Space


Who's the Expert?

  • Associate professor in the department of Neurology with a focus on Neuromuscular disease.
  • Currently follows 90 MG patients and has 14 years experience treating myasthenic patients in an MGFA recognized MG center.
  • Familiar with all emerging MG therapies and currently uses Solaris with his patients.

Interview Goal:

To understand the current standard of care better and get the insights into Ra Pharma’s RA101495, Argenx’s ARGX-113, and Catalyst Pharma’s Firdapse

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.